Apple upgraded, Brinker initiated: Wall Street's top analyst calls

HSBC upgraded Apple to Buy from Hold and raised its price target to $366, citing an operational turning point and an AI-driven product pipeline.

Near-term upside bias versus prior Hold stance, with follow-through dependent on whether the market agrees with the AI turning-point thesis.

The article provides a specific, same-day analyst action (upgrade plus target hike) with a clear rationale, which can move positioning even without new company fundamentals.

Stephens initiated coverage of Brinker (Chili's) with an Overweight rating and a $220 price target, arguing the turnaround is now a share-gainer.

Moderate upside bias as the market digests the new $220 target and the improved visibility narrative.

This is an initiation note without new operational data or guidance; impact is more sentiment/positioning than a fundamental catalyst.

Stephens initiated coverage of Dutch Bros with an Overweight rating and an $80 price target, calling it a high-growth drive-through beverage platform.

Potential near-term positive drift, but likely limited without additional company-specific new disclosures.

The article contains only analyst framing and target setting, not new earnings, guidance, or operational prints.

Canaccord initiated coverage of Jazz Pharmaceuticals with a Buy rating and $290 price target, highlighting a shift toward higher-value oncology versus oxybate risk.

Mild-to-moderate upside bias if investors buy into the oncology mix shift thesis.

Initiation notes are informative but not a primary catalyst like earnings, trial results, or guidance.

Canaccord initiated coverage of Eton Pharmaceuticals with a Buy rating and $60 price target, describing a pivot to ultra-rare disease focus in niche pediatric areas.

Potential speculative upside bias, but magnitude uncertain without near-term clinical or commercial catalysts in the text.

No new trial data, approvals, or financial disclosures are included, only analyst positioning and target setting.

Jefferies initiated coverage of Moody’s with a Buy rating and $610 price target, citing improving revenue growth drivers including AI infrastructure spend.

Gradual positive bias rather than a sharp move, unless the market treats the target as a meaningful re-rate catalyst.

The article is a coverage initiation with thesis statements, not a new earnings print or regulatory event.